Expanded Access Policy

Sironax is a global clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory, immunologic, and metabolic diseases. The company has built a diverse pipeline of programs targeting contributors of aging, degeneration, metabolic dysfunction, and inflammation.

Currently, our primary goal is to evaluate the safety and efficacy of our investigational therapies (which have not yet been approved by the U.S. Food and Drug Administration (FDA), so we may seek regulatory approval and eventually make them available to all patients who need them. Prior to regulatory approval, we believe that participation in a clinical trial is the best way for patients to gain access to our investigational therapies.

Expanded Access refers to an alternative pathway for patients with a serious or life-threatening disease or condition to gain access to investigational therapies outside of a clinical trial. At this time, Sironax is committed to delivering its investigational therapies to patients through clinical trials and is not currently providing access to its investigational therapies on an expanded access basis.

Sironax may revise this Expanded Access Policy at any time.